Darifenacin    (DrugBank: Darifenacin)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病1
13多発性硬化症/視神経脊髄炎2

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00892450
(ClinicalTrials.gov)
May 200928/4/2009Anticholinergic Therapy for Overactive Bladder in Parkinson's DiseaseAnticholinergic Therapy for Overactive Bladder in Parkinson's Disease: A Randomized, Double-blind, Crossover Pilot StudyParkinson's Disease;Overactive BladderDrug: Oxybutynin and darifenacinDepartment of Veterans AffairsNULLCompletedN/AN/ABoth12N/AUnited States

13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00845338
(ClinicalTrials.gov)
February 200716/2/2009Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor OveractivityA 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor OveractivityMultiple Sclerosis;Overactive DetrusorDrug: Darifenacin (BAY79-4998)BayerNULLTerminated18 YearsN/ABoth7Phase 2Germany
2EUCTR2006-002361-39-DE
(EUCTR)
01/12/200621/08/2006A 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and neurogenic detrusor overactivityA 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and neurogenic detrusor overactivity Neurogenic overactive bladder disaese in patients with multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10059617;Term: Overactive bladder
Trade Name: EMSELEX 7,5 mg Retardtabletten
Product Name: Darifenacin
Product Code: BAY 79-4998
INN or Proposed INN: Darifenacin
Trade Name: EMSELEX 15 mg Retardtabletten
Product Name: Darifenacin
Product Code: BAY 79-4998
INN or Proposed INN: Darifenacin
Bayer Vital GmbHNULLNot RecruitingFemale: yes
Male: yes
Germany